Abstract: Antibody plays a key role in disease prevention, diagnosis, and treatment. Therapeutic antibodies have a market over 100 billion dollars with indications for various diseases such as cancers, autoimmune diseases, and infectious diseases. However, the trade suffers from high costs and low success rate. To assess the developability of thousands or even millions of antibody candidates comprehensively, reasonably, and quickly so as to decrease the late stage failure of antibody development is the key problem need to be solved in the field of therapeutic antibody development. This paper reviewed the advances in experimental and bioinformatics studies on evaluation of the developability of therapeutic antibodies. The problems of existing researches were also summarized. Therefore, it would benefit the relevant scholars in their further studies.